Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly to the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, Pitt School of Medicine. Results will be disclosed in an oral presentation on June 5 at the 46th annual meeting of the American Society of Clinical Oncology.